$3.14
0.00% day before yesterday
Nasdaq, Aug 30, 01:19 am CET
ISIN
US00972D1054
Symbol
AKBA

Akebia Therapeutics, Inc. Stock price

$3.14
-0.37 10.54% 1M
+1.29 69.73% 6M
+1.24 65.26% YTD
+1.62 106.58% 1Y
+2.77 755.59% 3Y
-7.27 69.84% 5Y
-3.82 54.89% 10Y
-23.56 88.24% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.01 0.32%
ISIN
US00972D1054
Symbol
AKBA
Industry

Key metrics

Basic
Market capitalization
$832.6m
Enterprise Value
$742.3m
Net debt
positive
Cash
$137.3m
Shares outstanding
263.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.1 | 3.8
EV/Sales
3.6 | 3.4
EV/FCF
negative
P/B
28.5
Financial Health
Equity Ratio
-22.3%
Return on Equity
141.1%
ROCE
1.8%
ROIC
-
Debt/Equity
1.6
Financials (TTM | estimate)
Revenue
$203.7m | $221.4m
EBITDA
$22.0m | -
EBIT
$4.0m | $13.1m
Net Income
$-36.5m | $-18.8m
Free Cash Flow
$-2.6m
Growth (TTM | estimate)
Revenue
16.8% | 38.2%
EBITDA
817.1% | -
EBIT
111.9% | 128.3%
Net Income
9.8% | 72.9%
Free Cash Flow
93.5%
Margin (TTM | estimate)
Gross
83.2%
EBITDA
10.8% | -
EBIT
2.0%
Net
-17.9% | -8.5%
Free Cash Flow
-1.3%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
9.5%
Employees
181
Rev per Employee
$880.0k
Show more

Is Akebia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Akebia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
204 204
17% 17%
100%
- Direct Costs 34 34
10% 10%
17%
170 170
18% 18%
83%
- Selling and Administrative Expenses 106 106
6% 6%
52%
- Research and Development Expense 41 41
1% 1%
20%
22 22
817% 817%
11%
- Depreciation and Amortization 18 18
50% 50%
9%
EBIT (Operating Income) EBIT 3.99 3.99
112% 112%
2%
Net Profit -36 -36
10% 10%
-18%

In millions USD.

Don't miss a Thing! We will send you all news about Akebia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akebia Therapeutics, Inc. Stock News

Positive
Seeking Alpha
4 days ago
I'm bullish on Akebia at $3.13, viewing the 21% post-earnings dip as a buying opportunity ahead of major revenue catalysts. Vafseo's rapid adoption and DaVita's pilot could double Akebia's addressable dialysis market, driving significant near-term revenue growth and profitability. Despite a mixed EPS, strong topline growth and stable Auryxia sales highlight Akebia's transition from speculative ...
Neutral
GlobeNewsWire
4 days ago
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C.
More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO John Butler
Employees 181
Founded 2007
Website akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today